Skip to main content

Table 2 The relarionship between GPS score and clinicopathological characteristics

From: Prognostic value of preoperative high-sensitivity modified Glasgow prognostic score in advanced colon cancer: a retrospective observational study

variable

GPS 0

GPS 1

GPS 2

P Value

(N = 409)

(N = 117)

(N = 68)

Age

(years)

   

0.046

< 75

290

48.8%

81

13.6%

38

6.4%

 

≥75

119

20.0%

36

19.7%

30

11.4%

 

Sex

       

0.075

female

168

28.3%

35

5.9%

29

4.9%

 

male

241

40.6%

117

19.7%

68

11.4%

 

BMI

       

0.039

≥18.5

328

58.5%

108

19.3%

54

9.6%

 

< 18.5

48

8.6%

9

1.6%

14

2.5%

 

tumor location

       

0.008

right side

159

26.8%

60

10.1%

37

6.2%

 

left side

250

42.1%

57

9.6%

31

5.2%

 

opearation approach

       

0.02

open

236

39.8%

80

13.5%

49

8.3%

 

lap

172

29.0%

37

6.2%

19

3.2%

 

Tumor size

(cm)

      

< 0.001

 

< 5

279

48.4%

52

9.0%

16

2.8%

 
 

≥5

118

20.5%

60

10.4%

51

8.9%

 

T

       

0.011

T2/3

342

57.6%

99

16.7%

47

7.9%

 

T4

67

11.3%

18

3.0%

21

3.5%

 

N

       

0.016

N0

196

33.1%

67

11.3%

44

7.4%

 

N1/2/3

213

35.8%

50

8.4%

24

4.0%

 

CEA

(ng/ml)

      

0.361

< 5

263

49.0%

69

12.8%

39

7.3%

 

≥5

108

20.1%

35

6.5%

23

4.3%

 

CA19–9

(U/ml)

      

0.588

< 37

302

56.5%

83

15.5%

43

8.1%

 

≥37

74

13.9%

18

3.4%

14

2.6%

 
  1. Abbreviation: GPS Glasgow Prognostic Score, BMI body mass index, CEA carcinoembryonic antigen; CA19–9 carbohydrate antigen 19–9
  2. P-values < 0.05 were considered to indicate statistical significance